Inhibikase Therapeutics, Inc. (NASDAQ: IKT) ('Inhibikase” or 'Company”), a clinical-stage pharmaceutical company developing ...

Inhibikase Therapeutics, Inc. (NASDAQ: IKT) ('Inhibikase” or 'Company”), a clinical-stage pharmaceutical company developing ...

In patients naïve to HER2-targeted therapy, the objective response rate was 71% with a median duration of response of 9.2 months.

Researchers from The University of Texas at Dallas' Center for Advanced Pain Studies (CAPS) and their colleagues have made a ...

A newly discovered neuron-released enzyme could transform pain treatment and reveal deeper secrets of how the brain learns.

On 13 November 2025, Merck Sharp & Dohme LLC initiated a study is to learn if people who receive patritumab deruxtecan (also ...

New research reveals that neurons release a little-understood extracellular kinase called VLK to strengthen synaptic ...

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics (CGEM) announced the companies have initiated the rolling submission of a New Drug Application to the U.S. Food and Drug Administration ...

The nod brings Bayer face-to-face in the market with Boehringer Ingelheim and AstraZeneca, each of which has its own HER2 ...

Cullinan Therapeutics (CGEM) and Otsuka Holdings (OTSKF) subsidiaries Taiho Oncology and Taiho Pharmaceutical have initiated the rolling ...

NDA based on data from global ARROS-1 Phase 1/2 clinical trial FDA assigns PDUFA target action date of September 18, 2026 CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/ ...

The FDA has granted approval to sevabertinib (Hyrnuo) for the treatment of patients with locally advanced or metastatic, ...